Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Tineke Casneuf"'
Autor:
Justin Cha, Cody J. Boehner, Nikhil C. Munshi, Romanos Sklavenitis-Pistofidis, Kwee Yong, Chip Stewart, Karma Salem, Eliezer M. Van Allen, Jihye Park, Yu-Tzu Tai, Andrew Dunford, Shankara Anand, Lorenzo Trippa, Amaro Taylor-Weiner, Jacob P. Laubach, Mark Bustoros, Benny Zhitomirsky, Robert A. Redd, Selina J Chavda, Irene M. Ghobrial, Shaji Kumar, Paul G. Richardson, Kenneth C. Anderson, François Aguet, Tarek H. Mouhieddine, P. Leif Bergsagel, Gad Getz, Mahshid Rahmat, Tineke Casneuf, Meletios A. Dimopoulos, Liudmila Elagina, Carl Jannes Neuse, Salomon Manier, Elizabeth A. Morgan, Ignaty Leshchiner, Efstathis Kastritis
Publikováno v:
J Clin Oncol
PURPOSE Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The disco
Autor:
Torben Plesner, Saad Z. Usmani, Koen Van der Borght, Homer Adams, Greet Vanhoof, Amy Sasser, Henk M. Lokhorst, Tineke Casneuf, Jakub Krejcik, Inger S. Nijhof, Tina Smets, Christopher Chiu, Hugo Ceulemans, Sagar Lonial, Niels W.C.J. van de Donk, Tuna Mutis, Frederik Stevenaert, Yann Abraham, Jaime Bald
Publikováno v:
Adams, H C, Stevenaert, F, Krejcik, J, Van der Borght, K, Smets, T, Bald, J, Abraham, Y, Ceulemans, H, Chiu, C, Vanhoof, G, Usmani, S Z, Plesner, T, Lonial, S, Nijhof, I, Lokhorst, H M, Mutis, T, van de Donk, N W C J, Sasser, A K & Casneuf, T 2019, ' High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action ', Cytometry. Part A, vol. 95, no. 3, pp. 279-289 . https://doi.org/10.1002/cyto.a.23693
Cytometry Part A, 95(3), 279-289
Adams, H C, Stevenaert, F, Krejcik, J, Van der Borght, K, Smets, T, Bald, J, Abraham, Y, Ceulemans, H, Chiu, C, Vanhoof, G, Usmani, S Z, Plesner, T, Lonial, S, Nijhof, I, Lokhorst, H M, Mutis, T, van de Donk, N W C J, Sasser, A K & Casneuf, T 2019, ' High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action ', Cytometry Part A, vol. 95, no. 3, pp. 279-289 . https://doi.org/10.1002/cyto.a.23693
Cytometry Part A, 95(3), 279-289
Adams, H C, Stevenaert, F, Krejcik, J, Van der Borght, K, Smets, T, Bald, J, Abraham, Y, Ceulemans, H, Chiu, C, Vanhoof, G, Usmani, S Z, Plesner, T, Lonial, S, Nijhof, I, Lokhorst, H M, Mutis, T, van de Donk, N W C J, Sasser, A K & Casneuf, T 2019, ' High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action ', Cytometry Part A, vol. 95, no. 3, pp. 279-289 . https://doi.org/10.1002/cyto.a.23693
Daratumumab is a CD38-targeted human monoclonal antibody with direct anti-myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory multiple myeloma (RRMM) patients treated with daratumumab revealed cytotoxic T-cell expansion an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b1d8fa08423cee70f92f2f3a32022b
https://findresearcher.sdu.dk:8443/ws/files/149065141/High_Parameter_Mass_Cytometry_Evaluation_of_....pdf
https://findresearcher.sdu.dk:8443/ws/files/149065141/High_Parameter_Mass_Cytometry_Evaluation_of_....pdf
Autor:
Tineke Casneuf, Inger S. Nijhof, Alessandro Di Cara, Berris van Kessel, Sagar Lonial, Tuna Mutis, Paul G. Richardson, Niels W.C.J. van de Donk, Sonja Zweegman, Paul W. H. I. Parren, Christopher Chiu, A. Kate Sasser, Henk M. Lokhorst, Saad Z. Usmani
Publikováno v:
van de Donk, N W C J, Casneuf, T, Di Cara, A, Parren, P W, Zweegman, S, van Kessel, B, Lokhorst, H M, Usmani, S Z, Lonial, S, Richardson, P G, Chiu, C, Mutis, T, Nijhof, I S & Sasser, A K 2019, ' Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma ', British Journal of Haematology, vol. 184, no. 3, pp. 475-479 . https://doi.org/10.1111/bjh.15122
British Journal of Haematology, 184(3), 475-479. Wiley-Blackwell
British Journal of Haematology, 184(3), 475-479. Wiley-Blackwell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30b70c75616640e4eb1767a7a0e25861
https://research.vumc.nl/en/publications/cdfb3d9d-1d2f-472c-8601-f6faeb13707a
https://research.vumc.nl/en/publications/cdfb3d9d-1d2f-472c-8601-f6faeb13707a
Autor:
Christopher Chiu, Nizar J. Bahlis, Jesús F. San-Miguel, Katja Weisel, Sagar Lonial, Torben Plesner, Andrew Spencer, Jon Ukropec, Shinsuke Iida, Saad Z. Usmani, Tineke Casneuf, Xiang Qin, Ming Qi, Linda Okonkwo, Philippe Moreau, Hervé Avet-Loiseau, Sonali Trivedi, Christopher Joseph Velas
Publikováno v:
Avet-Loiseau, H, San-Miguel, J F, Casneuf, T, Iida, S, Lonial, S, Usmani, S Z, Spencer, A, Moreau, P, Plesner, T, Weisel, K, Ukropec, J, Okonkwo, L, Trivedi, S, Velas, C J, Qin, X, Qi, M, Chiu, C & Bahlis, N 2018, ' Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor ', Blood, vol. 132, no. Suppl. 1 . https://doi.org/10.1182/blood-2018-99-113177
Introduction: Daratumumab (DARA) is a human IgGκ mAb targeting CD38 with both direct on-tumor and immunomodulatory mechanisms of action, and has been approved as monotherapy for RRMM and in combination with standard of care (SOC) regimens for RRMM a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abaede72db40c6c43ee87c7cbf4703a8
https://portal.findresearcher.sdu.dk/da/publications/5e267ade-0e41-49a4-adf2-a3caa051032f
https://portal.findresearcher.sdu.dk/da/publications/5e267ade-0e41-49a4-adf2-a3caa051032f
Autor:
Tineke Casneuf, Katherine Rigby, Christopher Chiu, Saad Z. Usmani, A. Kate Sasser, David M. Foureau, Lawrence J. Druhan, Imran Khan
Publikováno v:
Experimental Hematology & Oncology
Experimental Hematology & Oncology, Vol 7, Iss 1, Pp 1-7 (2018)
Experimental Hematology & Oncology, Vol 7, Iss 1, Pp 1-7 (2018)
Background Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple myeloma wi
Autor:
Philippe Moreau, Nizar J. Bahlis, Jesús F. San-Miguel, Kihyun Kim, Kaida Wu, Shinsuke Iida, Gordon Cook, Hervé Avet-Loiseau, Nushmia Z. Khokhar, Ajai Chari, A. Kate Sasser, Andrew Belch, Naoki Takezako, Jonathan L. Kaufman, Lisa O'Rourke, H. Miles Prince, Christopher Chiu, Lotfi Benboubker, Marc Lalancette, Saad Z. Usmani, Jordan M. Schecter, P. Joy Ho, James Morton, Jin Seok Kim, Heather J. Sutherland, Darrell White, Tara Cochrane, Albert Oriol, Tineke Casneuf, Meletios A. Dimopoulos, Hila Magen, David Soong, Merav Leiba
Publikováno v:
Haematologica
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow-up and include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e1d9f1ec1e0b3824ac7004150f04151
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5344
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5344
Autor:
Asher Chanan-Khan, Ajay K. Nooka, Wolney Barreto, Pieter Sonneveld, Suzanne Lentzsch, Meral Beksac, Katja Weisel, Paolo Corradini, Tineke Casneuf, Hervé Avet-Loiseau, Cindy Lee, A. Kate Sasser, Emma C. Scott, Vania Hungria, Roberto Ovilla, David Soong, Maria-Victoria Mateos, Christopher Chiu, Jae Cheol Jo, Piruntha Thiyagarajah, Tamás Masszi, Ivan Spicka, Andrew Spencer, Alberto Bosi, Je-Jung Lee, Birgitta Lauri, Tomer M Mark, Ho Jin Shin, Michele Cavo, Chang-Ki Min, Ming Qi, Himal Amin, Noemi Horvath, Mark-David Levin, Jordan M. Schecter, Marcelo Capra, Hang Quach
Publikováno v:
Haematologica, 103(12), 2079-2087. Ferrata Storti Foundation
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce3a1e1a76e903b4c2728c9fd6d22163
https://pure.eur.nl/en/publications/4909c9e9-c50a-478c-8154-f8989510a57a
https://pure.eur.nl/en/publications/4909c9e9-c50a-478c-8154-f8989510a57a
Autor:
Sagar Lonial, Xu Steven Xu, Xiaoyu Yan, Imran Khan, Christopher Chiu, Amy Axel, Pamela L. Clemens, Niels W.C.J. van de Donk, Tineke Casneuf, A. Kate Sasser, Homer Adams, Henk M. Lokhorst, Torben Plesner, Tahamtan Ahmadi
Publikováno v:
Casneuf, T, Xu, X S, Adams, H C, Axel, A E, Chiu, C, Khan, I, Ahmadi, T, Yan, X, Lonial, S, Plesner, T, Lokhorst, H M, van de Donk, N W C J, Clemens, P L & Sasser, A K 2017, ' Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma ', Blood, vol. 1, no. 23, pp. 2105-2114 . https://doi.org/10.1182/bloodadvances.2017006866
Blood, 1(23), 2105-2114. American Society of Hematology
Casneuf, T, Xu, X S, Adams, H C, Axel, A E, Chiu, C, Khan, I, Ahmadi, T, Yan, X, Lonial, S, Plesner, T, Lokhorst, H M, van de Donk, N W C J, Clemens, P L & Sasser, A K 2017, ' Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma ', Blood Advances, vol. 1, no. 23, pp. 2105-2114 . https://doi.org/10.1182/bloodadvances.2017006866
Blood, 1(23), 2105-2114. American Society of Hematology
Casneuf, T, Xu, X S, Adams, H C, Axel, A E, Chiu, C, Khan, I, Ahmadi, T, Yan, X, Lonial, S, Plesner, T, Lokhorst, H M, van de Donk, N W C J, Clemens, P L & Sasser, A K 2017, ' Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma ', Blood Advances, vol. 1, no. 23, pp. 2105-2114 . https://doi.org/10.1182/bloodadvances.2017006866
Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated clinical activity and a manageable safety profile in monotherapy and combination therapy clinical trials in relapsed and/or refractory multiple myeloma. CD38 is expre
Autor:
Mark van Duin, Tineke Casneuf, Niels W.C.J. van de Donk, Inger S. Nijhof, A. Kate Sasser, Andries C. Bloem, Berris van Kessel, Henk M. Lokhorst, Monique C. Minnema, Christopher Chiu, Tuna Mutis, Khaja Syed, Sonja Zweegman, Pieter Sonneveld, Jeroen F. van Velzen, Amy Axel, Richard W.J. Groen
Publikováno v:
Blood, 128(7), 959-970. American Society of Hematology
Blood, 128(7), 959. American Society of Hematology
Nijhof, I S, Casneuf, T, van Velzen, J, van Kessel, B, Axel, A E, Syed, K, Groen, R W J, van Duin, M, Sonneveld, P, Minnema, M C, Zweegman, S, Chiu, C, Bloem, A C, Mutis, T, Lokhorst, H M, Sasser, A K & van de Donk, N W C J 2016, ' CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma ', Blood, vol. 128, no. 7, pp. 959-970 . https://doi.org/10.1182/blood-2016-03-703439
Blood, 128(7), 959. American Society of Hematology
Nijhof, I S, Casneuf, T, van Velzen, J, van Kessel, B, Axel, A E, Syed, K, Groen, R W J, van Duin, M, Sonneveld, P, Minnema, M C, Zweegman, S, Chiu, C, Bloem, A C, Mutis, T, Lokhorst, H M, Sasser, A K & van de Donk, N W C J 2016, ' CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma ', Blood, vol. 128, no. 7, pp. 959-970 . https://doi.org/10.1182/blood-2016-03-703439
The anti-CD38 monoclonal antibody daratumumab is well tolerated and has high single agent activity in heavily pretreated relapsed and refractory multiple myeloma (MM). However, not all patients respond, and many patients eventually develop progressiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::416034364097f629d9565e3733a4a688
https://research.vumc.nl/en/publications/bd75e655-af9f-4c5f-8d86-37d1f2ae52df
https://research.vumc.nl/en/publications/bd75e655-af9f-4c5f-8d86-37d1f2ae52df
Autor:
Andrew Spencer, Je-Jung Lee, Vania Hungria, Christopher Chiu, Tineke Casneuf, Katja Weisel, Ming Qi, Jordan M. Schecter, Markus Munder, Suzanne Lentzsch, Maria-Victoria Mateos, Emma C. Scott, Xiang Qin, Piruntha Thiyagarajah, Tomer M Mark, Hang Quach, Pieter Sonneveld, Ajay K. Nooka, Himal Amin
Publikováno v:
Hematological Oncology. 35:388-389
8036 Background: Daratumumab (D), a human, CD38-targeting mAb, is well tolerated and induces deep and durable responses in patients (pts) with RRMM. We provide an update of CASTOR (NCT02136134), a multicenter, phase 3, randomized study of DVd vs Vd i